 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of 39.00 per share. The gross proceeds from this offering are expected to be 97.5 million, before deducting underwriting discounts and commissions and oth 